EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An optimised lipid nanoparticle platform enables efficient CRISPR/Cas9 genome editing in hard-to-transfect cells

Xinpu Yang, Rui Sang, Gyorgy Hutvagner, Alex W Hewitt, Diangeng Li, Yi Li, Wei Deng

Acta Biomaterialia · 2026-07 · 218 · 432-444

DOI: 10.1016/j.actbio.2026.05.044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-07. Verfasst von Xinpu Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Hauptthemen laut MEDLINE: Lipids, CRISPR-Cas Systems, Nanoparticles, Gene Editing. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Education, Australian Government, Cancer Institute NSW, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipidsCRISPR-Cas SystemsNanoparticlesGene EditingTransfectionHumansHEK293 CellsCell Line, TumorLiposomes

Stichwörter der Autor:innen

CRISPR/Cas9Gene editingHard-to-transfect cellsLipid nanoparticles

Substanzen

LipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
  • Graduate School of Biomedical Engineering, Faculty of Engineering, UNSW Sydney, NSW, 2052, Australia.
  • Menzies Institute for Medical Research, University of Tasmania, TAS, 7005, Australia.
  • Department of Academic Research, Beijing Ditan Hospital, Capital Medical University, National Center for Infectious Diseases (BeiJing), 8th Jingshun East Road, Beijing, 100015, China.
  • Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, 1 Yixueyuan Rd., Chongqing, 400016, China; Department of Nephrology, Metabolism an…
  • School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Electronic address: wei.deng@uts.edu.au.

Förderung

  • Department of Education, Australian Government
  • Cancer Institute NSW
  • National Health and Medical Research Council

Zitieren

APA

Yang, X., Sang, R., Hutvagner, G., Hewitt, A. W., Li, D., Li, Y., & Deng, W. (2026). An optimised lipid nanoparticle platform enables efficient CRISPR/Cas9 genome editing in hard-to-transfect cells. Acta Biomaterialia, 218, 432-444. https://doi.org/10.1016/j.actbio.2026.05.044

Vancouver

Yang X, Sang R, Hutvagner G, Hewitt AW, Li D, Li Y, et al. An optimised lipid nanoparticle platform enables efficient CRISPR/Cas9 genome editing in hard-to-transfect cells. Acta Biomaterialia. 2026;218:432-444. doi:10.1016/j.actbio.2026.05.044

BibTeX
@article{Yang2026,
  author = {Yang, Xinpu and Sang, Rui and Hutvagner, Gyorgy and Hewitt, Alex W and Li, Diangeng and Li, Yi and Deng, Wei},
  title = {An optimised lipid nanoparticle platform enables efficient CRISPR/Cas9 genome editing in hard-to-transfect cells},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {218},
  pages = {432--444},
  doi = {10.1016/j.actbio.2026.05.044}
}
Kostenlos starten →